2016 Annual Meeting

Tumor Immunology: Implications for TNM Staging and Therapeutics

Room CC Ballroom 6 E, March 14 2016, 1:00pm to 5:00pm

Description

Special Course

Tumor Immunology: Implications for TNM Staging and Therapeutics
Monday, March 14, 2016
1:00 PM-5:00 PM

Course Directors: Janis M. Taube, MD, and Robert Anders, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD

Course Description:
The focus of this course is TNM-Immune staging and the emerging use of surgical pathology specimens for immune-based assays, including immunologic biomarkers for therapeutic selection and monitoring.  With the recent FDA approvals for PD-1/PD-L1 checkpoint inhibitors and their associated companion and complimentary diagnostics, surgical pathologists are being asked to incorporate such tests into their routine practice.

Upon completion of this educational activity, participants should be able to:

  1. Summarize how the activity of checkpoint agents differs from that of more traditional therapeutics.
  2. Summarize the latest concepts regarding the immune contexture of malignant neoplasms.
  3. Discuss the histologic features associated with adaptive immune resistance.
  4. Understand the limitations of PD-L1 evaluation.
  5. Identify additional markers and associated detection techniques that will likely be employed in future Immunopathology assays

Agenda

1:00 PM

Immune Checkpoints, Checkpoint Blockade Therapy, and Rational Patient Selection: An Overview
Janis M. Taube, MD, Johns Hopkins University SOM, Baltimore, MD
Upon Completion of this educational activity, participants should be able to:

  1. Familiarize participants with the immune synapse
  2. Introduce checkpoint blocking agents and how their activity and side effects differ from other therapeutic agents
  3. Summarize recent FDA approvals for this class of therapeutics and the specific indications.

1:15 PM

The Immune Contexture in Human Tumors: Impact on Clinical Outcome
Jerome Galon, MD, PhD, Chief Inserm Laboratory, Integrative Cancer Immunology, Paris, France
Upon Completion of this educational activity, participants should be able to:

  1. Identify the key inflammatory components in a malignant neoplasm
  2. Summarize how the Immunoscore compares to current TNM staging
  3. Understand how an Immunoscore is calculated and the status of the Immunoscore Task force in validating this approach

1:50 PM

Adaptive Immune Resistance: Biomarker Implications
Robert Anders, MD, PhD, Johns Hopkins University SOM, Baltimore, MD
Upon Completion of this educational activity, participants should be able to:

  1. Discuss the histologic features of adaptive immune resistance by tumor
  2. Discuss the limitations of PD-L1 IHC evaluation in predicting response to anti-PD-1/PD-L1 therapies
  3. Explain the pre- and post-analytic variables that influence determining if a malignancy expresses PD-L1

2:25 PM

Comparison of Different Assay Techniques for Immune Markers
David Rimm, MD, PhD, Yale University, New Haven, CT
Upon Completion of this educational activity, participants should be able to:

  1. Compare current chromogenic IHC testing methods for PD-L1
  2. Highlight advantages for methods beyond chromogenic IHC for measuring PD-L1 and other checkpoint expression in the tumor microenvironment
  3. Explain the advantage of quantitative assessment of immune markers

 

3:00 PM

Break

 

4:00 PM

Immunoarchitectural Features of the Tumor Microenvironment: Beyond PD-L1
Scott Rodig, MD, PhD, Brigham and Women’s Hospital, Boston, MA
Upon Completion of this educational activity, participants should be able to:

  1. Identify additional checkpoints and other markers in the tumor microenvironment thought to have clinical impact
  2. Compare and contrast the tumor microenvironment of hematologic malignancies as compared to solid tumors
  3. Summarize state-of-the-art methods used to evaluate the immunoarchitecture of FFPE specimens, including multiplex IHC/IF

Meetings

home-circle-inset-1
view more